Argent BioPharma (ASX:RGT) Licenses Four Cannabis Genotypes to Thai Phytomed Under a 15% Profit Royalty

Sonal Goyal

27 October 2026 12:13 PM AEDT

Argent BioPharma (ASX:RGT) Licenses Four Cannabis Genotypes to Thai Phytomed Under a 15% Profit Royalty

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Argent signed a 10-year exclusive worldwide licence over four proprietary cannabis genotypes with Thai Phytomed International.
Argent will receive a royalty of 15% of profits from commercialisation of the licensed genetics.
Argent retains ownership of the underlying genetics and associated intellectual property.
Argent may terminate the licence if no commercial sale is made within 24 months after delivery of the genetic material.

Argent BioPharma Ltd (ASX:RGT) announced on 27 October 2026 that it has entered into a 10-year exclusive worldwide licensing agreement with Thai Phytomed International Co., Ltd. (TPI) covering four cannabis genotypes owned within the Argent BioPharma Group.

Terms of the Licence

The agreement covers four genotypes, MXC-THC-10/3, MXC-THC-81/5, MXC-THC-40/3 and MXC-THC-40/2. TPI receives exclusive worldwide rights to cultivate, propagate, process, extract, manufacture, market, distribute, import and export the licensed genetics and products derived from them, including flower, extracts and cannabinoid active pharmaceutical ingredients, subject to regulatory requirements. The initial term is 10 years and can be renewed for a further 10 years on the same terms by written confirmation from both parties.

The licence is not a sale or transfer of ownership. The genetics and related intellectual property remain with Argent BioPharma (UK) Ltd, formerly MGC Pharma (UK) Ltd, which is wholly owned by Argent. Argent keeps the right to use the genetics for internal pharmaceutical research and development, and the agreement excludes CannEpil, CimetrA, the company’s other pharmaceutical products, clinical dossiers, formulations and drug delivery technologies.

Commercial Structure and Strategy

Argent will receive a royalty of 15% of profits generated from commercialisation of the licensed genetics. Royalties will be calculated quarterly and apply to commercialisation by TPI, by TPI-controlled operating entities and through permitted sublicensing. TPI is responsible for funding commercial development and for obtaining and maintaining the cultivation, manufacturing, quality, product, import and export approvals required in each market.

Argent said the transaction supports its strategy of extracting value from legacy cannabis assets through licensing, while directing its own resources to pharmaceutical, immune-modulation and anti-inflammatory development. It follows the global licensing of CannEpil. The agreement does not set a sales volume or a minimum payment, and the release states no royalty income figure.

Why This Could Matter

The royalty is based on profits, not revenue, so any income to Argent depends on TPI completing regulatory approvals, funding commercialisation and generating profit in the markets it enters. The 24-month termination right applies if no commercial sale is made after delivery of the genetic material, which sets a time limit on the start of commercial activity.

Closing View

Argent BioPharma has licensed four cannabis genotypes to a Thai partner in return for a profit-based royalty, while retaining ownership and its pharmaceutical focus. No financial value for the royalty was disclosed, and timing depends on TPI’s approvals.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.